Johnson & Johnson
NYSE: JNJ
$164.16
-$0.66 (-0.4%)
Closing Price on September 20, 2024
JNJ Articles
U.S. pharmaceutical and biotech stocks may have considerable upside if Credit Suisse's views come to pass. But this part of the market has not come without controversy in the past year and a half.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
The top analyst upgrades, downgrades and other research calls from Monday include Albermarle, Blue Apron, Box, Dish Network, GM, Transocean and Under Armour.
Published:
Last Updated:
Apple, P&G, Johnson & Johnson, and Verizon led the DJIA lower on Thursday.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Biogen, Electronic Arts, Gap, Intuit, Johnson & Johnson, 3M, Intercept Pharmaceutical and AutoZone.
Published:
Last Updated:
Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day.
Published:
Last Updated:
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
Published:
Last Updated:
Achillion Pharmaceuticals saw its shares slump early on Monday after the firm announced that its hepatitis C license and collaboration agreement with Janssen had been terminated.
Published:
Last Updated:
Johnson & Johnson, Cisco Systems, Disney, and Caterpillar led the DJIA downward on Wednesday.
Published:
Last Updated:
Companies included on the S&P 500 index bought back more than $500 billion in stock last year and have bought back more than $4 trillion in shares since 2008.
Published:
Last Updated:
One thing investors wanted to hear on conference calls this earnings season was how companies are responding to Amazon. One industry that escaped such queries was defense, but that may have been an...
Published:
Last Updated:
Merck, Johnson & Johnson, DuPont, and Verizon led the 20 stocks that were heading for a lower close just minutes before the closing bell.
Published:
Last Updated:
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host disease.
Published:
Last Updated:
General Electric, Nike, Home Depot, and Johnson & Johnson led the DJIA lower Monday.
Published:
Last Updated:
Stocks have pulled back a tad from all-time highs, and the market indexes were indicated to have a slight drop on Friday morning. Still, indexes remain right at all time highs and this bull market is...
Published:
Last Updated: